Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Alzheimer Disease: early-phase trial registry
155 of 312 indexed Alzheimer Disease trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #25 of 28,707 conditions by registered trial count.
312 US clinical trials · 155 currently recruiting · #25 of 28,707 conditions by registered trial count
Alzheimer Disease: 312 US clinical trials tracked, 155 recruiting.
Alzheimer Disease is the subject of 312 registered US clinical trials on ClinicalTrials.gov, 155 of them currently open to new participants. 26 are in Phase 3-4 (later-stage) and 104 in Phase 1-2 (earlier-stage). The most active sponsor is Eli Lilly and Company, running 13 of these trials.
Enrollment posture brief
Registry condition alzheimer-disease
OPEN 155 | RECR 50% | LATE 26 | EARLY 104 | RANK #25 | SPON 13
Volume-matched condition peers
Nearest open-share peer: PTSD (50% recruiting · 155 trials)
Alzheimer Disease lists 155 open slots (50% of 312 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Alzheimer Disease on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Alzheimer Disease is recruiting above its size-band peers.
155 of 312 indexed trials (49.7%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Alzheimer Disease trials is spread across many organizations.
Eli Lilly and Company accounts for 13 of 312 trials (4.2%). 178 distinct sponsors appear on at least one study for this condition label.
-
Typical Alzheimer Disease enrolment sits around 100 participants.
Median target enrolment is 100 among the 307 trials that report a genuine target (sentinel values excluded). 151 of those (49.2%) plan for fewer than 100 participants.
-
Alzheimer Disease research is mostly interventional.
255 interventional and 57 observational studies make up this index (81.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
312 total, page 1 of 7
Alzheimer Prevention Trials (APT) Webstudy
University of Southern California
NCT03638583
Primary Care Detection of Cognitive Impairment Leveraging Health & Consumer Technologies in Underserved Communities: The MyCog Trial
Northwestern University
NCT05607732
Alzheimer's National Registry for Treatment and Diagnostics(ALZ-NET)
Alzheimer's Disease and Related Disorders Association
NCT06170268
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Sanguine Biosciences
NCT05635266
Longitudinal Cognitive Assessment by BoCA
Alzheimer's Light
NCT04114994
Alzheimer's Disease Genetics Study
Indiana University
NCT00064870
NYSCF Scientific Discovery Biobank
New York Stem Cell Foundation Research Institute
NCT06203106
Late Onset Alzheimer's Disease
Columbia University
NCT05010603
A Real-World Comparative Study of Donanemab (LY3002813) Plus Usual Care Versus Usual Care Alone in US Participants With Early Symptomatic Alzheimer's Disease
Eli Lilly and Company
NCT06566170
Epidemiology and Biomarker Study in Alzheimer's Disease
Eli Lilly and Company
NCT07142954
Evaluating Novel Healthcare Approaches to Nurturing and Caring for Hospitalized Elders
University of Michigan
NCT05929703
Computerized Tests of Cognitive Decline in Presymptomatic Alzheimer's Disease
Neurobehavioral Systems
NCT04800588
Alzheimer's Disease Treatment With Combination of 40Hz Light and Cognitive Therapy
Alzheimer's Light
NCT03657745
Promoting Goals-of-Care Discussions for Patients With Memory Problems and Their Caregivers
University of Washington
NCT05596760
Study to Understand Novel Biomarkers in Researching Dementia
Washington University School of Medicine
NCT06547099
DC Longitudinal Study on Aging and Specimen Bank
Georgetown University
NCT03702907
Vanderbilt Memory and Aging Project
Vanderbilt University Medical Center
NCT05372159
Tennessee Alzheimer's Project
Vanderbilt University Medical Center
NCT05372172
Using the EHR to Advance Genomic Medicine Across a Diverse Health System
University of Pennsylvania
NCT06377033
F 18 T807 Tau PET Imaging of Alzheimer's Disease
Tammie L. S. Benzinger, MD, PhD
NCT02414347
Longitudinal Early-onset Alzheimer's Disease Study Protocol
Indiana University
NCT03507257
Palliative Care Education in Assisted Living for Dementia Care Providers (PCEAL-DCP)
University of South Florida
NCT06722352
Trial to Reduce Antimicrobial Use in Nursing Home Residents With Alzheimer's Disease and Other Dementias 2.0
Hebrew SeniorLife
NCT05950607
Georgia Memory Net Anti-Amyloid Monoclonal Antibody Registry
Emory University
NCT05999084
Neuroimaging in Healthy Aging and Senile Dementia (HASD_IND)
Tammie L. S. Benzinger, MD, PhD
NCT04579120
Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease
Mayo Clinic
NCT03821857
Triage Survey for Neurology Research Eligibility
Adams Clinical
NCT06104852
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
Bristol-Myers Squibb
NCT06937229
Arizona Alzheimer's Disease Research Center (ADRC)
Banner Health
NCT05405075
Implement and Test Visual Consent Template and Process
Washington University School of Medicine
NCT06804837
Cognitive Neurology Unit Clinical Registry
Beth Israel Deaconess Medical Center
NCT05925621
ADRC Clinical Cohort (Alzheimer's Disease)
Duke University
NCT06703541
Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase
University of Alabama, Tuscaloo
NCT05820919
Trial-Ready Cohort-Down Syndrome (TRC-DS)
University of Southern California
NCT04165109
Evaluating the Efficacy of the Pain Identification and Communication Toolkit
Weill Medical College of Cornell University
NCT06168604
A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)
Alzheimer's Disease Cooperative Study (ADCS)
NCT06223360
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
Karuna Therapeutics
NCT06585787
Anxiety Sensitivity Treatment to Reduce Anxiety in Alzheimer's
Florida State University
NCT05748613
Imaging Biomarkers in Preclinical and Symptomatic AD
Tammie L. S. Benzinger, MD, PhD
NCT04134923
Connect-Home: Alzheimer's Disease and Related Dementias
University of North Carolina, Chapel Hill
NCT06840587
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)
Bristol-Myers Squibb
NCT07011745
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
Bristol-Myers Squibb
NCT07011732
Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease
Lighthouse Pharmaceuticals
NCT06847321
Biomarker Exploration in Aging, Cognition and Neurodegeneration
University of California, Irvine
NCT03860857
HEARS-NPS: Addressing Hearing Loss as a Common Unmet Contributor of Neuropsychiatric Symptoms
Johns Hopkins University
NCT06930560
Testing the Effects of a Text Message Caregiver Support Intervention for Latinos
University of Kansas Medical Center
NCT06728436
Exercise to Improve Brain Health in Older African Americans
Rutgers, The State University of New Jersey
NCT05597124
Is Obstructive Sleep Apnea Important in the Development of Alzheimer's Disease?
University of California, San Diego
NCT05094271
Discovery and Validation of Genetic Variants Affecting Microglial Activation in Alzheimer's Disease
Columbia University
NCT04840979
Alzheimer"s Imaging Biomarkers in Obesity
Cyrus A Raji
NCT05077579
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 53 |
| Phase 2 | 51 |
| Phase 3 | 18 |
| Phase 4 | 8 |
Top Sponsors
Named interventions
Most-linked intervention names on Alzheimer Disease records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Alzheimer Disease trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Alzheimer Disease page
312 registered trials, 155 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 155 Alzheimer Disease trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Eli Lilly and Company sponsors the most Alzheimer Disease trials on record, review their full trial history before evaluating a specific study. See Eli Lilly and Company's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Alzheimer Disease condition card totals 312 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.